Evidence map›Paper›PMID 36678900›Full record

ArticlePharmaceutics2023

Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader.

Giuseppe Ermondi, Diego Garcia Jimenez, Matteo Rossi Sebastiano, Jan Kihlberg, Giulia Caron

Abstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giuseppe ErmondiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Quarello 15, 10135 Torino, Italy.ORCID 0000-0003-3710-3102
Diego Garcia JimenezDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Quarello 15, 10135 Torino, Italy.ORCID 0000-0002-7247-1480
Matteo Rossi SebastianoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Quarello 15, 10135 Torino, Italy.ORCID 0000-0002-9925-1904
Jan KihlbergDepartment of Chemistry-BMC, Uppsala University, SE-75123 Uppsala, Sweden.
Giulia CaronDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Quarello 15, 10135 Torino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chameleonicity (the capacity of a molecule to adapt its conformations to the environment) may help to identify orally bioavailable drugs in the beyond-Rule-of-5 chemical space. Computational methods to predict the chameleonic behaviour of degraders have not yet been reported and the identification of molecular chameleons still relies on experimental evidence. Therefore, there is a need to tune predictions with experimental data. Here, we employ PROTAC-1 (a passively cell-permeable degrader), for which NMR and physicochemical data prove the chameleonic behaviour, to benchmark the capacity of two conformational sampling algorithms and selection schemes. To characterize the conformational ensembles in both polar and nonpolar environments, we compute three molecular properties proven to be essential for cell permeability: conformer shape (radius of gyration), polarity (3D PSA), and the number of intramolecular hydrogen bonds. Energetic criteria were also considered. Infographics monitored the simultaneous variation of those properties in computed and NMR conformers. Overall, we provide key points for tuning conformational sampling tools to reproduce PROTAC-1 chameleonicity according to NMR evidence. This study is expected to improve the design of PROTAC drugs and the development of computational sustainable strategies to exploit the potential of new modalities in drug discovery.

Indexed as

bRo5conformational samplingearly drug discoverymolecular chameleonNMRPROTAC

Identifiers

PMID36678900
PMCPMC9861353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.